Type 2 diabetes mellitus (T2DM) is a multi-factorial disease, and its prevalence continues to rise. Lifestyle changes remain a key component of the interventions that require patient participation to initiate and sustain. Additionally, several pharmacological options are available to address the various pathophysiological factors involved in T2DM. Some of these agents have demonstrated cardiovascular benefit, and the renoprotective effect of certain medications has also been investigated with promising results. This knowledge helps PCPs to use appropriate pharmacological agents to individualize treatment plans while following the principles of patient centered care.   

Tina K. Thethi, MD, MPH, FACE

Associate Investigator, AdventHealth, Translational Research Institute, Endocrinologist, AdventHealth, Diabetes Institute, Orlando, FL

What do primary care providers need to know  about hypertension, anxiety, and fibromyalgia? Join cardiologist Karol Watson, psychiatrist Jeffrey Rado, and rheumatologist Peng Thim Fan as they review important questions, they get asked about these topics!

Peng Thim Fan, MD, FACP

Clinical Professor of Medicine, Division of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA

Jeffrey Rado, MD, MPH, FAPA

Associate Professor, Northwestern University, Feinberg School of Medicine, Chicago, IL,

Karol E. Watson, MD, PhD

Professor of Medicine/Cardiology, David Geffen School of Medicine at UCLA, Co-director, UCLA Program in Preventive Cardiology, David Geffen School of Medicine at UCLA, Director, UCLA Barbra Streisand Women's Heart Health Program, David Geffen School of Medicine at UCLA, Los Angeles, CA

This activity will provide an evidence-based approach to the diagnosis and management of irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC), with minimal diagnostic testing. The faculty will describe evidence-based treatment guidelines and discuss the efficacy of over-the-counter and prescription agents prioritized within the guidelines. This will help you navigate the progress from patient education to diet plus over-the-counter agents to prescription agents.

Philip Schoenfeld, MD, MSEd, MSc

Chief (Emeritus) - Gastroenterology Section, John D. Dingell VA Medical Center, Detroit, MI

Supported by Allergan and Ironwood Pharmaceuticals, Inc. Salix Pharmaceuticals

Neutralizing monoclonal antibodies (mAbs) first received emergency use authorization (EUA) in November 2020 for treating at-risk patients with COVID-19--and the field has continued to evolve ever since. This presentation provides an update in the latest evidence showing reduced severe illness and hospitalization in patients treated with neutralizing mAbs. The expert presenters will explain the science and practical issues of using mAbs to treat patients with COVID-19 in outpatient and skilled nursing facility settings while also answering your questions from their multidisciplinary perspectives. 
 
This educational activity includes: 
• Best practices for identifying appropriate patients for mAb infusions and connecting these patients with infusion therapy 
• Overview of clinical trial data for efficacy and safety of treatment with neutralizing mAbs alone and in combination with other mAbs
• Frontline stories of establishing mAbs infusion programs, including preparing, administering, monitoring, and reporting 
• Discussion of issues identified through analysis of responses to a survey conducted with Pri-Med learners 

Peter Chen, MD

Professor of Medicine and Biomedical Sciences, Director, Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, CA,

Chad R. Worz, PharmD, BCGP, FASCP

Chief Executive, The American Society of Consultant Pharmacists, Alexandria, VA,

Supported by Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Kidney and electrolyte problems affect nearly 15% of the U.S. adult population. Yet, many health care providers are intimidated by patients with these complex issues. Through the structure of five fictional patient cases, expert faculty will give HCPs the tools that they need to care for patients with acute kidney injury and chronic kidney disease while utilizing current best practices. This session will also explore patient-centered treatments for some common electrolyte abnormalities.

Rajeev Raghavan, MD

Associate Professor of Medicine, Baylor College of Medicine, Houston, TX

Melanie Hoenig, MD

Associate Professor, Harvard Medical School, Boston, MA

Neurology Pearls will provide the primary care clinician with the most up-to-date knowledge needed to identify and treat commonly seen neurological outpatient diagnoses, including headache, dizziness, peripheral neuropathy, tremor, and seizure vs. syncope.  

Katherine Carroll, MD

Assistant Professor of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL